| Key
Features: |
|
| Title
and year of the Document |
Chinese Pharmacoeconomic
Evaluation Guideline 2006 |
| Affiliation
of authors |
PE Center, Chinese Medical
Doctor Association |
| Main
policy objective |
Providing recommendations
for conduct of C/E studies in order to improve their
quality, credibility and comparability To support
the decision-making process with sound C/E data |
| Standard
reporting format included |
Yes |
| Disclosure
of funding/ author’s interests |
Yes |
| Target
audience |
Who conduct PE evaluation
or evaluate the PE studies(decision makers) |
| Perspective |
Societal & health care
sector |
| Indication |
Approved indication |
| Target
population |
Be clearly specify |
| Subgroup
analysis |
Yes |
| Choice
of comparator |
Most prevalent treatment,
most inexpensive treatment, no treatment |
| Time
horizon |
Should be clearly described
and appropriate to the disease and treatment. Long-term
effects should be emphasized |
| Assumptions
required |
Yes |
| Preferred
analytical technique |
CMA, CEA, CUA |
| Costs
to be included |
Depends on the aim of the
study. All costs that are relevant must be distinguished
and presented in detail. Report indirect costs separately. |
| Source
of costs |
Latest unit prices, give
references. |
| Modeling |
Yes, requires details |
| Systematic
review of evidences |
Yes, encourage meta-analysis |
| Preference
for effectiveness over efficacy |
Yes. RCTs, retrospective
studies, intervention trials, patient databases,
modeling all acceptable |
| Preferred
outcome measure |
Effectiveness by intention-to-treat
principle, and expressed in natural units or QALY |
| Preferred
method to derive utility |
SG, TTO or VAS. Should
justify the selection |
| Equity
issues stated |
Yes |
| Discounting
costs |
Yes, rates explained ,
Presented with and without discounting |
| Discounting
outcomes |
Yes, rates explained ,
Presented with and without discounting |
| Sensitivity
analysis-parameters and range |
All key uncertain parameters,
within a defined area, or best/worst case scenario |
| Sensitivity
analysis-methods |
One-way, multi-way, may
be probabilistic analysis Details be given of the
statistical tests performed |
| Presenting
results |
Most clear way, Reports
both in disaggregated and aggregated form |
| Incremental
analysis |
Yes |
| Total
C/E |
Yes |
| Portability
of results (Generalizability) |
Yes, Studies must refer
to the national context |
| Financial
impact analysis |
Yes |
